The U.S. intravenous immunoglobulin (IVIG) market was valued at USD 5.74 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 7.7% from 2023 to 2030. Rising demand for immunoglobulin replacement therapy, particularly for primary immunodeficiency diseases (PIDD), and the introduction of new products are supporting market growth. Expanded treatment options, greater awareness of immune-related disorders, and increasing adoption of home-based infusion services are also influencing the market’s development.

Key Market Trends & Insights

• Growing demand for immunoglobulin replacement therapy: Increasing diagnosis and treatment of primary immunodeficiency diseases is strengthening demand for IVIG products in the United States.
• Expansion of home infusion services: Home-based IVIG administration gained momentum during the COVID-19 pandemic, partly because it can reduce the need for healthcare facility visits. This approach is expected to remain relevant for patients requiring ongoing treatment.
• Supply chain vulnerabilities: Pandemic-related demand for plasma-derived products and a decline in plasma donations contributed to supply constraints. Because plasma fractionation requires time, disruptions became more apparent in early 2021.
• High treatment costs: The substantial cost of immunoglobulin therapy can limit access, particularly for patients without adequate insurance coverage or Medicare benefits.
• Product innovation and regulatory approvals: Pharmaceutical companies are pursuing new indications, product launches, and research initiatives to broaden treatment options for patients with immune-mediated and other disorders.

Download a free sample report or claim your copy of this full market intelligence report

Market Dynamics: Demand, Accessibility, and Innovation

Increasing Use Across Multiple Disease Categories

IVIG replacement therapy is used to manage immunodeficiency and selected autoimmune, neurological, and hematological disorders. In addition to FDA-approved indications, clinicians may use IVIG for certain conditions outside its approved labeling, including Guillain-Barré syndrome, myasthenia gravis, and multifocal motor neuropathy. Treatment decisions depend on the individual condition, clinical evidence, and physician assessment.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is another important application. Increased utilization of IVIG for CIDP reflects its role in managing patients who require immunoglobulin-based treatment.

Home Infusion Reshapes Treatment Delivery

Home infusion became more prominent during the COVID-19 pandemic as healthcare providers sought ways to administer treatment while limiting unnecessary hospital and clinic visits. For eligible patients, home-based administration can offer greater convenience and reduce travel requirements. Continued adoption will depend on patient suitability, clinical supervision, treatment protocols, and access to appropriate infusion services.

Plasma Supply Constraints Affect Product Availability

The pandemic placed considerable pressure on the U.S. IVIG supply chain. Higher demand for plasma-derived products, combined with reduced plasma donations, created shortages and disrupted product availability. The time required to collect plasma and complete fractionation meant that supply disruptions persisted beyond the initial phase of the pandemic.

These challenges highlight the importance of maintaining reliable plasma collection networks, manufacturing capacity, and distribution systems to support consistent access to immunoglobulin therapies.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

High Costs Remain a Barrier to Treatment Access

The cost of IVIG treatment remains a significant challenge for patients and healthcare providers. According to the National Center for Biotechnology Information (NCBI), the average U.S. treatment session cost was approximately USD 9,720 in 2021. The cited analysis estimated a monthly cost of USD 41,796 for 4.3 sessions, while annual treatment costs for a patient with CIDP could exceed USD 136,000.

These historical figures illustrate the financial burden associated with recurring immunoglobulin therapy. Actual expenses vary according to the treatment regimen, dosage, care setting, reimbursement arrangements, and insurance coverage.

New Approvals Expand Treatment Options

Product approvals and indication expansions are helping manufacturers address evolving clinical needs. In July 2021, the U.S. Food and Drug Administration (FDA) approved Octagam 10% for the treatment of adults with dermatomyositis, expanding the range of available treatment options for this patient population.

Further research into immunoglobulin therapies could create additional opportunities for market participants. However, adoption will depend on clinical evidence, regulatory outcomes, product availability, and the suitability of each therapy for its intended indication.

Key Companies & Market Developments

Competition in the U.S. IVIG market is shaped by product development, research and development (R&D), regulatory approvals, strategic partnerships, and mergers and acquisitions. Manufacturers are working to expand their product portfolios and address demand across established and emerging therapeutic applications.

In April 2023, Takeda Pharmaceutical Company Limited received FDA approval to expand the use of Hyqvia, an immune globulin infusion 10% combined with recombinant human hyaluronidase. The treatment is indicated for primary immunodeficiency in patients aged two years and older. This development illustrates how regulatory milestones can broaden treatment access for eligible patient groups.

Prominent companies operating in the U.S. intravenous immunoglobulin market include:

• Biotest AG
• China Biologic Products Holdings, Inc.
• Octapharma AG
• LFB Biotechnologies S.A.S.
• Takeda Pharmaceutical Company Limited
• Bio Products Laboratory Ltd.
• Pfizer, Inc.
• CSL

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today